More on RARE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $26.90 |
|
|||
| Open | $27.37 | ||||
| 52 Wk High | $117.12 | ||||
| 52 Wk Low | $46.52 | ||||
| Day High | $28.00 | ||||
| Day Low | $27.20 | ||||
| P/E | N/A | ||||
| EPS | $-1.97 | ||||
| Volume | 162,172 | ||||
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Tactical Resources Announces Exchange Ratio for Business Combination with Plum Acquisition Corp. III
- Ultragenyx Pharma (RARE) PT Raised to $77 at Jefferies
- Tactical Resources and Plum Acquisition Corp. III Announce Receipt of Nasdaq Approval; Transaction Expected to Close on July 28, 2026
- Ultragenyx releases 2025 impact report on rare disease programs
- Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
- Ultragenyx Pharma (RARE) PT Raised to $40 at RBC Capital
- Form 4 Ultragenyx Pharmaceutica For: Jul 01 Filed by: Horn Howard
- Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard
- Calidi Biotherapeutics adds biopharma veteran Corsee Sanders to board
Entities mentioned with RARE
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- JPMorgan | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
